-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 22
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
New—Duration of #fracture prevention after #zoledronate treatment in #women with #osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years https://t.co/RuyuGjo4fK #osteopenia